-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

28 Resolving Human Hematopoietic Stem Cell Functional Heterogeneity with ATP2B1 Surface Expression

Program: Oral and Poster Abstracts
Type: Oral
Session: 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Epigenetic and Metabolic Control of Hematopoiesis
Hematology Disease Topics & Pathways:
Research, Fundamental Science
Saturday, December 7, 2024: 10:15 AM

Angelica Varesi1,2, Murtaza S. Nagree, PhD2*, Andy G.X. Zeng, BSc1,2, Sayyam Shah2*, Hyerin Kim2*, John Edgar Dick1,2 and Stephanie Z. Xie, PhD2

1Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada
2Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

A pool of human long-term hematopoietic stem cells (LT-HSC) maintains life-long hematopoiesis by generating shorter-living progenitors that ultimately replenish mature cells. Molecular (transcriptional, epigenetic) and functional analysis have revealed that highly purified CD49f+LT-HSC are heterogeneous, with inflammation response as one prominent driver of heterogeneity. To uncover putative surface markers to help untangle CD49f+ LT-HSC heterogeneity, we leveraged our recent discovery of two human HSC subsets following recovery from inflammatory challenge; one that does not respond and the other subset that retains memory of prior inflammation (Zeng et al, in revision). Among transcriptional candidates encoding surface proteins that were enriched in the HSC inflammatory memory subset, we identified ATPase plasma membrane Ca2+ transporting 1 (ATP2B1/PMCA1). ATP2B1was intriguing, because calcium flux was reported to impact embryonic stem cell and HSC function (MacDougall et al.,Cell Stem Cell 2019; Luchsinger et al., Cell Stem Cell, 2019).

We analyzed ATP2B1 immunophenotypic expression in the human CD34+CD38CD90+ HSC compartment and performed in vitro single cell differentiation assays and in vivo serial xenotransplantation assays to determine if CD49f LT-HSC could be functionally stratified. ATP2B1 and CD49f surface expression in human neonatal cord blood (CB) and adult mobilized peripheral blood (mPB) sources revealed three immunophenotypic subpopulations: CD49f+ATP2B1+ (P1 LT-HSC), CD49f+ATP2B1 (P2 LT-HSC), and CD49f ATP2B1 (P3 HSC). The proportion of ATP2B1-expressing P1 LT-HSC is higher in neonatal than adult sources (10% in CB vs 3.5% in mPB) in the CD34+CD38CD90+ compartment. Single-cell erythroid-myeloid differentiation assays on MS5-stroma following index sorting for ATP2B1 and CD49f expression in CB CD34+CD38CD90+ HSC revealed increased total clonogenicity and CD34+ output from P1 LT-HSC relative to the other 2 subsets. Moreover, serial replating clonogenic assays showed increasing output from P1 LT-HSC>P2 LT-HSC>P3 HSC and increased maintenance of immunophenotypic CD34+ cells. Of note, P3 HSC and CD90CD49fST-HSC showed similar limited serial clonogenic potential confirming previous reports that these subpopulations have limited self-renewal. We transplanted the three CD34+CD38CD90+ HSC subsets into immunodeficient mice and found repopulating potential was similar at 4 weeks post-transplant. However, at 20 weeks post-transplantation, human CD45 repopulation as well as the proportion of CD34+CD19 cells was highest to lowest in mice transplanted with P1 LT-HSC>P2 LT-HSC>P3 HSC. As a surrogate for self-renewing LT-HSC (Garcia-Prat et al., Cell Stem Cell 2021), we undertook lysotracker flow cytometry analysis on P1 LT-HSC and P2 LT-HSC cultured for 16 hours. This assay showed that CB and mPB ATP2B1-expressing LT-HSC are significantly enriched for lysosomes, further supporting the notion that P1 LT-HSC may have superior self-renewal. Direct measurement of self-renewal by quantitative secondary limiting dilution transplantation of 20 week primary transplants of P1 LT-HSC and P2 LT-HSC demonstrated 6.9-fold increased stem cell frequency for P1 LT-HSC. Analysis of the combined single-cell transcriptional and epigenetic landscape from 10x Genomics Multiome profiling within P1 and P2 LT-HSC are ongoing. In conclusion, ATP2B1 surface protein expression bifurcates CD49f+ LT-HSC into two discrete functional LT-HSC subpopulations which will enable unprecedented mechanistic resolution into human HSC heterogeneity.

Disclosures: Dick: Pfizer/Trillium Therapeutics: Patents & Royalties: IP interest in SIRP-a therapeutics; Bristol-Myers Squibb/Celgene: Research Funding.

*signifies non-member of ASH